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Cysteine proteases (falcipains) of Plasmodium falciparum are potential targets for antimalarial chemother-
apy, since they have been shown to be involved in important cellular functions such as hemoglobin degradation
and invasion/rupture of red blood cells during parasite life cycle. The role of falcipain-1 at the asexual blood
stages of the parasite still remains uncertain. This is mainly due to a lack of methods to prepare this protein
in an active form. In order to obtain biologically active falcipain-1, a number of falcipain-1 constructs were
designed and a systematic assessment of the refolding conditions was done. We describe here the expression,
purification, and characterization of a falcipain-1 construct encoding mature falcipain-1 and 35 amino acids
from the C-terminal of the pro domain. Recombinant falcipain-1 was overexpressed in the form of inclusion
bodies, solubilized, and purified by Ni2-nitrilotriacetic acid affinity chromatography under denaturing con-
ditions. A systemic approach was then followed to optimize refolding parameters. An optimum refolding
condition was obtained, and the yield of the purified refolded falcipain-1 was1 mg/liter. Activity of the protein
was analyzed by fluorometric and gelatin degradation assays. Immunolocalization studies using anti-falci-
pain-1 sera revealed a distinct staining at the apical end of the P. falciparummerozoites. Previous studies using
falcipain-1-specific inhibitors have suggested a role of falcipain-1 in merozoite invasion. Based on its local-
ization and its role in invasion, we analyzed the immunogenicity of falcipain-1 in mice, followed by heterologous
challenge with Plasmodium yoelii sporozoites. Our results suggest a possible role of falcipain-1 in merozoite
invasion.
Malaria is a one of the most important infectious diseases
caused by protozoan parasites of the genus Plasmodium. The
most virulent human malaria parasite, Plasmodium falciparum,
is responsible for the death of 1.5 to 2.7 million people world-
wide annually (3). With the emergence of insecticide-resistant
mosquitoes and drug-resistant parasites, there is an urgent
need to identify new drug targets and develop new antimalari-
als (26). Malarial proteases are attractive antimalarial targets
because of their crucial role in parasite development, espe-
cially in the process of host erythrocyte rupture/invasion and
hemoglobin degradation (27). Data mining approaches have
identified a large number of putative proteases encoded in the
P. falciparum genome (48). Depending upon their mode of
action, these proteases have been classified into five different
groups (aspartic, cysteine, serine, metallo-, and threonine pro-
teases). Among these different proteases, the roles of cysteine
proteases (falcipains) and aspartic proteases (plasmepsins)
have been best characterized through the use of their specific
inhibitors (2, 8, 19, 20, 36).
Four falcipains that have been identified so far in the P.
falciparum genome are falcipain-1 (FP-1), falcipain-2 and -2
(now known as FP-2A and -2B), and falcipain-3 (FP-3). Falci-
pain-2A, -2B, and -3 have been shown to be involved in hemo-
globin degradation (37, 40, 41). A recent knockout study of
falcipain-2A suggested that falcipain-2B takes over the func-
tions of falcipain-2A in the knockout parasites (39). However,
the physiological role of falcipain-1 in asexual blood stages of
the parasite still remains uncertain. Salas et al. (33) and Mal-
hotra et al. (17) have suggested that falcipain-1 acts as a he-
moglobinase. Later, Greenbaum et al. (10) showed that falci-
pain-1 is active during the invasive merozoite stage, and
falcipain-1 specific inhibitors blocked parasite invasion of host
erythrocyte but had no effect on the parasite hemoglobin deg-
radation activity (10). Recently, two independent knockout
studies have suggested a role of falcipain-1 in oocyst produc-
tion but not in erythrocyte development (7, 38).
Despite being the first cysteine protease to be discovered in
Plasmodium, falcipain-1 has still not been well characterized.
Difficulties in production of recombinant protease have pre-
vented its detailed biochemical and functional characteriza-
tion. Although Salas et al. (33) were able to produce falci-
pain-1 in soluble form using a baculovirus expression system,
characterization of the recombinant protein was hampered by
low yield and the simultaneous expression and interference of
baculoviral cysteine proteases (33). More recently, FP-1 ex-
pressed as a fusion protein with maltose-binding protein
(MBP) in Escherichia coli was once again obtained in low yields
(9). Interestingly, the above two recombinant falcipain-1 prep-
arations showed dissimilar activities; the baculovirus prepara-
tion was found to be active against the fluorogenic peptide
substrate benzyloxycarbonyl-Phe-Arg-7-amino-4-methyl-cou-
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marin (Z-F-R-AMC) at acidic pH, along with having hemo-
globin degradation activity, while the MBP-fused falcipain-1
was active at neutral pH against the same peptide substrate but
showed no hemoglobin degradation activity.
High-level expression of a protein is a prerequisite for struc-
tural and functional characterization studies. We therefore
designed a number of falcipain-1 constructs, analyzed them for
high-level expression in E. coli, and optimized the refolding
conditions. One of the refolded proteins was tested for its
vaccine potential using a heterologous Plasmodium yoelii mouse
challenge model.
MATERIALS AND METHODS
Materials. Restriction endonucleases and T4 DNA ligase were purchased
from New England Biolabs (Beverly, MA). Taq polymerase was from Bangalore
Genei (Bangalore, India). Mouse anti-His sera, Ni2-nitrilotriacetic acid (NTA)
agarose, pQE30 plasmid DNA, and M15 cells were from QIAGEN, Hilden,
Germany. Isopropyl--D-thiogalactopyranoside (IPTG), dithiothreitol (DTT),
Q-Sepharose, and Superdex 75 column matrices for gel filtration purposes were
acquired from Amersham Pharmacia. Complete Freund’s adjuvant (CFA), in-
complete Freund’s adjuvant (IFA), Coomassie brilliant blue R-250, horseradish
peroxidase-conjugated anti-mouse secondary immunoglobulin G (IgG), and
4,6-diamidinophenylindole (DAPI) were purchased from Sigma, St. Louis,
MO.
Cloning and expression of falcipain-1 constructs. Five different constructs, i.e.,
F1.1 (1.7 kb), F1.2 (1.1 kb), F1.3 (714 bp), F1.4 (819 bp), and F1.5 (798 bp),
encoding the mature region and different lengths of the pro domain regions of
falcipain-1 gene were designed (Fig. 1). DNA fragments coding for these con-
structs were amplified from genomic DNA of P. falciparum by using different
primer sets. The full-length falcipain-1 gene was amplified using primers A
(forward, 5ATG GTT GCC ATA AAA GAA ATG 3) and B (reverse, 5 CCC
AAG CTT CAA GAT AGG ATA GAA GAC 3), the F1.1 gene fragment was
amplified using primers C (forward, 5 CCG AAT TCG GAA TTA CTT CGC
GTT CTT TTA 3) and B (reverse), gene fragment F1.3 was amplified using
primers D (forward, 5 CCG GAA TTC GGT ACC TGA AAT ATT AGA T3)
and B (reverse), and for F1.4 PCR amplification was done using primers E
(forward, 5 GAT CGG ATC CAT AGA AAA ATA TTC GAA A 3) and B
(reverse). The amplified falcipain-1 fragments were cloned in pGEM-T vector
and excised using the respective endonucleases (restriction sites are shown in
boldface), and the excised fragments were cloned in a number of E. coli expres-
sion plasmids (pET22b, pET32b, and pQE30) digested with the corresponding
endonucleases. The pET22b and pET32b constructs were transformed into
BL21(DE3) and AD494(DE3) E. coli cells, while pQE30 constructs were trans-
formed into M15(pREP4) E. coli cells. To express F1.2 protein, the gene frag-
ment was excised from the full-length falcipain-1 construct with BamHI and
HindIII sites and cloned into pQE30 vector digested with the corresponding
enzymes. The hybrid construct F1.5 was generated by cloning the mature region
of falcipain-1 in the falcipain-2-expressing pQE30 clone described previously by
Kumar et al. (14) at EcoRI and HindIII sites. The final F1.5 construct thus
contained 28 amino acids from the pro domain of falcipain-2 and the mature
region of falcipain-1. The constructs F1.4 and F1.5 were transformed into
M15(pREP4) cells, while the F1.2 construct was transformed into AD494(DE3)
cells. The recombinant clones were analyzed by restriction digestions, and pos-
itive clones were sequenced with an automated DNA sequencer.
Expression of the recombinant proteins was analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting
using anti-His antibodies. The recombinant proteins expressed in different pro-
karyotic expression vectors were analyzed by 10% SDS-PAGE for their subcel-
lular localization. All the expressed recombinant proteins were purified on
Ni2-NTA columns under denaturing conditions. Refolding conditions for each
recombinant protein were standardized on a 16-well cell culture plate. Table 1
lists the refolding conditions used for the Ni2-NTA-purified F1.4 construct.
Similar conditions were tried for all the recombinant Ni2-NTA purified pro-
teins. The purified and refolded falcipain-1 proteins were analyzed for enzymatic
activity by using a fluorogenic substrate, Z-F-R-AMC. Based on the yield and
enzymatic activity, the recombinant protein F1.4 that contained the mature
region and a 35-amino-acid pro domain of falcipain-1 was used for large-scale
purification and characterization.
Large-scale expression and refolding of F1.4. Large-scale expression of F1.4
was carried out as follows. Bacteria transformed using pQE30-F1.4 plasmid were
grown in 6 liters of culture medium to mid-log phase at 37°C. Cultures were
induced with IPTG (1 mM) and allowed to grow further for 4 h at 37°C. Cells
were harvested (21 g [wet weight]), washed with ice-cold 100 mM Tris-HCl and
10 mM EDTA (pH 7.4), further disrupted by sonication for 30 cycles with
10-second pulsing and 10-second cooling intervals, and centrifuged at 12,000 
g for 30 min at 4°C. The pellet obtained was washed twice with 2 M urea, 20 mM
Tris-HCl, 2.5% and Triton X-100 (pH 8.0), centrifuged at 17,000  g for 30 min
at 4°C, and solubilized in buffer A (6 M Gu-HCl, 20 mM Tris-HCl, 250 mM
NaCl, 20 mM imidazole, pH 8.0) at room temperature (RT) for 60 min with
gentle shaking on the rotator. Insoluble material was separated by centrifugation
at 20,000  g for 30 min at 4°C. The supernatant was incubated for 60 min at RT
with Ni2-NTA resin preequilibrated with buffer A. The protein-bound resin was
loaded onto a column and washed with 10 bed volumes each of (i) 6 M Gu-HCl,
20 mM Tris-HCl, 250 mM NaCl (pH 8.0), 8 M urea, 20 mM Tris-HCl, and 500
mM NaCl (pH 8.0) and (ii) 8 M urea, 20 mM Tris-HCl, and 30 mM imidazole
(pH 8.0). Bound proteins were eluted with 8 M urea, 20 mM Tris-HCl, and 1 M
imidazole (pH 8.0). The eluted proteins were analyzed by 10% SDS-PAGE and
quantified by the Bradford dye-binding assay.
Thirty millligrams of Ni2-NTA-purified F1.4 was reduced with 10 mM DTT,
and refolding was carried out in an optimized refolding buffer (100 mM Tris-
HCl, 1 mM EDTA, 250 mM L-arginine, 2.5 mM reduced Lglutathione [GSH],
0.25 mM oxidized Lglutathione [GSSG] and 20% glycerol, pH 8.0) with a 100-
fold dilution of ice-cold reduced denatured falcipain-1 to a final concentration of
20 g/ml. Refolding was allowed to proceed at 10°C for 36 h with stirring, and the
protein was concentrated using a tangential fast-flow concentrating system (Mil-
TABLE 1. Efficiency of refolding of F1.4 in a redox couple
GSH concn: % ActivityGSSG concn (mM)
10:1............................................................................................ 22.3
7.5:1........................................................................................... 15.5
5:1.............................................................................................. 8.2
2.5:1........................................................................................... 0
1:1.............................................................................................. 0
10:0.5......................................................................................... 17.1
7.5:0.5........................................................................................ 20.8
5:0.5........................................................................................... 30.0
2.5:0.5........................................................................................ 15.1
1:0.5........................................................................................... 4.3
10:0.25....................................................................................... 0
7.5:0.25...................................................................................... 0
5:0.25......................................................................................... 6.8
2.5:0.25......................................................................................100
1:0.25......................................................................................... 9.4
0.5:0.25...................................................................................... 7.6
FIG. 1. Schematic representation of falcipain-1 constructs. The
constructs vary with respect to the length of the pro regions: 253 amino
acids for F1.1, 119 amino acids for F1.2, no pro region for F1.3; 42
amino acids for F1.4, and 28 amino acids of the pro region of falci-
pain-2 for F1.5.
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lipore) to a final volume of 10 ml. An aliquot of the refolded falcipain-1 was
analyzed by 10% SDS PAGE.
Preparation of recombinant falcipain-2 protein. Recombinant falcipain-2 was
prepared as described previously by Shenai et al. (37) and Kumar et al. (14).
Enzyme activity of recombinant F1.4. Substrate gel analysis and fluorometric
assay were performed to determine the enzyme activity of recombinant falci-
pain-1. Substrate gel analysis was performed as previously described (29) using
SDS-PAGE under nonreducing conditions with gel copolymerized with 0.1%
(wt/vol) gelatin. Recombinant protein samples were mixed with the nonreducing
SDS-PAGE sample buffer and subjected to 10% SDS-PAGE under nonreducing
conditions. Subsequently, the gel was washed twice with 2.5% Triton X-100 for
30 min each. The washed gel was incubated overnight in activity buffer (100 mM
sodium acetate [pH.5.5], 10 mM DTT) and then stained with Coomassie brilliant
blue and destained as per the standard protocol.
Fluorometeric assays for the recombinant refolded proteins were carried out
in 3 ml assay buffer (100 mM sodium acetate [pH 5.5], 10 mM DTT) containing
200 nM enzyme. The fluorogenic substrate Z-F-R-AMC was added at 50 M,
and activity was monitored as the increase of fluorescence (excitation, 355 nm;
emission, 460 nm) for 30 min at RT with an LS50B Perkin-Elmer fluorometer.
For all assays the substrate concentration was saturating within the time courses
of studies, such that curves for fluorescence measured over time remained linear.
For inhibition studies, recombinant falcipain-1 was incubated with inhibitor for
10 min prior to the addition of substrate.
Characterization of F1.4 by PAGE and by gel permeation chromatography
and mobility shift analysis. Refolded and purified falcipain-1 (F1.4) was ana-
lyzed by gel permeation chromatography using a Sephadex G-75 column (Amer-
sham Pharmacia) on an AKTA fast protein liquid chromatography system (Amer-
sham Pharmacia). The column was equilibrated with 20 mM Tris and 150 mM
NaCl, pH 7.5. Standard peaks were acquired by running molecular weight pro-
tein markers. The void volume was determined by using blue dextran. Refolded
protein was injected through a 500-l loop, and the flow rate was maintained at
100 l/min.
Refolded F1.4 (4 to 10 g in 10 to 20 l) was incubated with and without DTT
at a final concentration of 100 mM at 37°C for 30 min. After this incubation,
equal volumes of nonreducing SDS-PAGE sample buffer were added and both
samples were boiled for 10 min. The samples were resolved by 10% SDS-PAGE
and visualized by Coomassie blue staining.
Immunization of mice and rabbits. Two groups of six BALB/c mice (4 to 6
weeks old) were immunized intramuscularly with 50 g of refolded F1.4 and
falcipain-2, respectively, with proteins formulated in CFA. A control group of
mice received only the adjuvant, emulsified in phosphate-buffered saline (PBS).
Boosters were given on days 21 and 42 postimmunization with IFA. Mice were
bled prior to immunization to collect preimmune sera. Blood samples were
collected on days 0, 14, 35, and 56 postimmunization, and sera were analyzed by
enzyme-linked immunosorbent assay (ELISA).
For rabbit immunization, two New Zealand White rabbits were immunized
with 150 g of recombinant falcipain-1 emulsified with CFA. Two booster im-
munizations were carried out on days 28 and 56 with protein formulated in IFA.
Rabbits were bled on days 0 (preimmune), 42, and 70, and sera were analyzed by
ELISA. Prior clearance for ethical animal experimentation was obtained for the
in vivo experiments.
ELISA. ELISAs were carried out to evaluate the antibody responses generated
against F1.4 in mice and rabbits. Briefly, 96-well microplates (Dynatech) were
coated with 100 ng of F1.4 protein in 0.06 M carbonate-bicarbonate buffer (pH
9.6). The plates were kept overnight at 4°C, and wells were blocked with 5%
low-fat milk in PBS (pH 7.2) for 1 h at room temperature. The antigen-coated
wells were sequentially incubated with the appropriate dilutions of the respective
antisera and optimally diluted with enzyme-labeled secondary antibody (horse-
radish peroxidase-conjugated anti-mouse IgG). In between these incubations,
plates were washed three times with 0.05% Tween 20 in PBS, followed by three
washes with PBS only. The enzyme reaction was developed with o-phenylenedi-
amine dihydrochloride-H2O2 in citrate phosphate buffer (pH 5.0) and stopped
with 8 N H2SO4, and the optical density (OD) and 490 nm was measured using
an ELISA microplate reader (Molecular Devices). On the basis of preimmune
sera giving an OD of 0.07  0.014 at a dilution of 1:200, an OD cutoff of 0.1
(mean  2 standard deviations) was selected for antibody titer determination.
Immunofluorescence assay. Antiserum to recombinant F1.4 was also tested in
an immunofluorescence assay for reactivity with falcipain-1 and yoelipain-1 in
the respective parasites. The assay was performed essentially as described earlier
(31, 44). Briefly, multispot parasite slides were made from P. falciparum culture
and from blood smears of P. yoelii-infected mice. The slides were air dried and
fixed with acetone-methanol (9:1) at RT for 40 min. Polyclonal antibodies raised
against F1.4 protein were diluted (1:500) with 0.5% bovine serum albumin in
PBS–0.05% Tween 20, and the slides were incubated with the diluted antibodies
in a sealed, moist box for 2 h at RT. The slides were washed with PBS–0.05%
Tween 20 and incubated with fluorescein isothiocyanate-conjugated goat anti-
mouse IgG (Sigma) at a 1:200 dilution in 0.5% bovine serum albumin in PBS for
1 h at room temperature in the dark. The slides were rewashed, air dried, and
mounted with an antifade solution to retard photobleaching (Bio-Rad). Fluo-
rescence was examined by use of a Nikon SE300 microscope with a 100 oil
immersion objective.
Immunoblot analysis. To prepare P. yoelii parasite lysate, BALB/c mice were
injected with 107 to 108 erythrocytes infected with P. yoelii nigeriensis. The course
of infection was followed by making thin smears from the tail blood of the mice
on alternate days. Infected mouse blood (50% parasitemia) was drawn, mixed
with heparin, washed by centrifugation three times in PBS at 700  g, and
passed through a CF 11 column to minimize the leukocyte contents (13). The
eluted parasitized erythrocytes were then lysed with saponin, washed with PBS,
and solubilized in SDS-PAGE buffer. P. yoelii lysate was subjected to 12%
SDS-PAGE, and immunoblotting was performed with nitrocellulose membranes
(Amersham Biosciences) blocked using 5% nonfat dry milk and 0.05% Tween 20
in PBS, pH 7.4. Blots were probed with anti-F1.4 antibody in phosphate-buffered
saline (pH 7.4) containing 0.5% milk and 0.05% Tween 20. The secondary
antibodies were horseradish peroxidase-conjugated anti-rabbit IgG (Sigma); re-
actions were detected using a West Pico Super Signal Enhanced Luminescence
kit (Pierce).
Parasite challenge. The protective efficacy of F1.4 was studied by heterologous
parasite challenge to immunized mice with sporozoites from the lethal mouse
malaria strain P. yoelii ND67. Briefly, mosquitoes were infected with P. yoelii
ND67 parasites, and thoracic regions were dissected out. The sporozoites were
prepared by homogenizing the thoracic regions in normal saline containing 2%
bovine serum albumin. Animals were challenged by intravenous inoculation of
104 sporozoites at 8 days after the last booster (day 50). Parasitemia was exam-
ined in Giemsa-stained thin and thick blood smears daily starting 4 days post-
challenge.
RESULTS
Cloning, expression, and purification of different falcipain-1
constructs. Five different falcipain-1 constructs (F1.1, F1.2,
F1.3, F1.4, and F1.5) were designed (Fig. 1). While the first
four constructs differed from each other with respect to the
length of the pro domain, the fifth construct (F1.5) consisted of
28 amino acids of the pro region of falcipain-2 and the full
mature region of falcipain-1. Four falcipain-1 fragments (F1.2,
F1.3, F1.4, and F1.5) were expressed in a number of E. coli
expression systems. Moderate to high-level expression was
seen for F1.2 in the pET32b system as a thioredoxin fusion, for
F1.3 in the pET22b vector, and for F1.4 and F1.5 in the pQE30
system (data not shown). We did not observe significant levels
of expression for the full-length falcipain-1 (F1.1) (data not
shown). All the recombinant falcipain-1 fragments were ex-
pressed in insoluble form. Purification of the recombinant pro-
teins under denatured conditions on Ni2-NTA affinity col-
umns yielded about 80 to 90% homogenous proteins (Fig. 2A).
The maximum yield and purity (5 mg/liter and 90% purity)
were obtained for F1.4 protein expressed in the pQE30 vector
system. These purified proteins were then refolded by rapidly
diluting the proteins to a final concentration of 20 g/ml with
buffers which varied with respect to the ratio of oxidized to
reduced glutathione. The refolded proteins were concentrated,
estimated, and analyzed for the protease activity using fluoro-
metric and gelatin hydrolysis assays on SDS-PAGE. Among
the four constructs (F1.2, F1.3, F1.4, and F1.5), F1.4 showed
the best yield after refolding in terms of protein amount and
enzyme activity. Table 1 shows the activities of F1.4 in 16
different refolding conditions. Based on these preliminary re-
sults, we decided to pursue large-scale expression and purifi-
cation of the F1.4 construct in the pQE30 expression system.
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Large-scale expression and refolding of F1.4. For the large-
scale production of recombinant F1.4, culture was grown at a
6-liter scale. Ni2-NTA purification and refolding were carried
out as described in Materials and Methods. During refolding a
substantial amount of protein precipitated out; this could be
due to the presence of aggregates of unfolded falcipain-1 pro-
tein. The soluble protein was concentrated using a tangential
fast-flow concentrating system from Millipore, and part of it
was dialyzed against buffer containing 100 mM sodium acetate
and 20% glycerol (pH 5.5) for 10 to 15 h before activity anal-
ysis. After refolding, the yield of the recombinant protein was
1 mg/liter.
Characterization of refolded F1.4. Refolded F1.4 was ana-
lyzed for its homogeneity by gel permeation chromatography.
Purified recombinant F1.4 migrated as a single major peak
(data not shown). F1.4 migrated as a 31-kDa protein on
SDS-PAGE and showed a mobility shift under reducing con-
ditions compared to nonreducing conditions, thereby suggest-
ing the formation of disulfide bonds (Fig. 2B). No dimers or
higher-order oligomers were observed under nonreducing con-
ditions on SDS-PAGE.
Activity analysis of F1.4. The enzyme activity of refolded
F1.4 was analyzed using a fluorogenic substrate, Z-F-R-AMC.
As shown in Fig. 3A, refolded F1.4 cleaved the fluorogenic
substrate, and the proteolytic activity was higher at acidic pH
than at neutral pH. The protease activity of the refolded pro-
tein was lost upon denaturation. E-64 at 10 M and leupeptin
at 100 M completely inhibited the proteolytic activity of the
enzyme. We failed to observe any hemoglobin degradation by
F1.4.
We also assessed the activity of F1.4 by gelatin SDS-PAGE
assay. A clearing was observed against the blue background at
a molecular mass of 32 kDa, suggesting a proteinase activity
(Fig. 3B).
Production of anti-falcipain-1 antibodies. Immune responses
against recombinant F1.4 formulated in CFA/IFA adjuvant in
mice as well as in rabbits were determined by ELISA at dif-
ferent time points. F1.4-specific antibody was detected after
the primary immunization, and antibody titers were boosted
with each subsequent booster. In both mice and rabbits, the
antibody response reached a peak after a second boost. The
end point titers obtained ranged between 0.9  106 and 1.3 
106 in mice, while two rabbits elicited titers of 2.8  106 and
3.0  106, respectively. The preimmune sera (day 0) or adju-
vant control sera did not show reactivity with the recombinant
protein in ELISA.
Detection of native falcipain-1 by anti-F1.4 antibodies. An-
tibodies to F1.4 raised in mice and rabbits tested positive in an
immunofluorescence assay against blood stages of P. falciparum.
Merozoites stained with an antibody to falcipain-1 showed a
distinct staining at the apical end of the parasite next to the
nucleus (Fig. 4A). A punctuate falcipain-1 staining pattern was
also observed in erythrocytic schizonts (Fig. 4B). In addition,
costaining was performed with antibodies to MSP-119 and the
micronemal protein EBA-175. Merging of the two staining
patterns revealed that compartments containing falcipain-1 are
distinct from the MSP-1- and EBA-175-containing compart-
ments (Fig. 4). The unique falcipain-1 location at the apical
end of the merozoites suggested a role of falcipain-1 either in
red blood cell (RBC) rupture or during reinvasion of host red
blood cells.
Detection of yoelipain-1 by anti-F1.4 antibodies. To find out
if anti-F1.4 antibody recognizes its ortholog yoelipain-1, we
performed Western blotting with P. yoelii lysate. As shown in
FIG. 2. (A) Coomassie blue-stained 10% SDS-polyacrylamide gel of Ni2-NTA-purified falcipain-1 fragments F1.2 (a), F1.3 (b), F1.4 (c), and
F1.5 (d). Lane M, Molecular mass markers (kDa). Arrows indicate positions of the falcipain-1 protein fragments. Lanes 1 and 2, elutes from
Ni2-NTA column. (B) Coomassie blue-stained SDS-polyacrylamide gel of purified and refolded F1.4. Lane 1, molecular mass markers (kDa); lane
2, reduced F1.4; lane 3, nonreduced F1.4.
VOL. 75, 2007 P. FALCIPARUM CYSTEINE PROTEASE WITH VACCINE POTENTIAL 2029
Fig. 5A, anti-F1.4 antiserum recognized a 34-kDa band in P.
yoelii lysate, while preimmune sera failed to recognize any
band. These results were further confirmed by immunofluores-
cence assay against blood stage P. yoelii parasites; a punctuate
staining was observed in P. yoelii schizonts (Fig. 5B). The
results of Western blotting and immunostaining suggested that
anti-F1.4 antibody significantly cross-reacts with the ortholog
yoelipain-1.
Protective efficacy of falcipain-1 in mice. Since falcipain-1-
specific inhibitors have been earlier shown to block merozoite
reinvasion of RBCs (10), we further assessed the protective
efficacy of falcipain-1 in a mouse model system. To do so, a
group of six mice were immunized with recombinant F1.4
formulated in CFA and in IFA. The control group was immu-
nized with adjuvant alone. Another group of six mice were
immunized with recombinant falcipain-2, a trophozoite stage
cysteine protease. Upon challenge with sporozoites (104) of the
lethal strain P. yoelii nigerensis ND67, mice immunized with
adjuvant alone developed a patent infection by day 4 to 5
postchallenge and reached a peak parasitemia of 85%  5%
on day 9  3 (Fig. 6A), while the mice immunized with falci-
pain-2 reached a peak parasitemia of 70%  5% on day 20 
3 (P  0.008). In comparison, mice immunized with F1.4 be-
came patent by day 6 to 7 postchallenge. This group showed
slower growth of parasites and a significantly lower peak par-
asitemia of 10%  5% on day 22 (P  0.0025). All the naı¨ve
and falcipain-2-immunized mice succumbed to infection by
days 15 and 20, respectively, whereas mice vaccinated with F1.4
survived until day 30. The mice immunized with the recombi-
nant F1.4 protein had a mean survival time of 30  4 days,
compared with 11  4 days for the naı¨ve mice (Fig. 6B). Death
in F1.4-immunized mice can be attributed to reasons other
than high parasitemia, as they maintained a fairly low para-
sitemia even before death.
DISCUSSION
Of the four falcipains observed in P. falciparum so far, fal-
cipain-2A, -2B, and -3 have been biochemically and function-
ally well characterized and shown to be involved in degradation
of hemoglobin and RBC membrane proteins (37, 40, 41). Al-
though it was the first cysteine protease to be described, the
role of falcipain-1 has remained unclear due to its relatively
low abundance in erythrocytic stages of the parasite and diffi-
culty in its expression using heterologous expression systems.
Attempts to produce falcipain-1 in baculovirus system (33)
or as a fusion protein in an E. coli system have not been
entirely satisfactory (9). Given the widespread experience with
FIG. 3. (A) Proteolytic activity of F1.4 at pH 5.5 and pH 7.0. Activity was analyzed for the hydrolysis of Z-F-R-AMC and represented as the
release of fluorescence in arbitrary fluorescence units measured over a period of 30 min (percentage of maximum activity). Error bars represent
the standard deviations of the results from three independent refolding experiments. (B) Activity analysis of F1.4 on SDS-PAGE with gelatin as
a substrate. Proteolysis is shown by a clear region on the gel as indicated by an arrow.
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and convenience of using E. coli as a heterologous system, we
decided to carry out a systematic study with the objective of
producing falcipain-1 in this system. However, most heterolo-
gous recombinant proteins expressed in E. coli are produced as
insoluble proteins, and many are expressed as fusion proteins
along with partners such as glutathione S-transferase or MBP,
which, in addition to being useful in affinity purification, are
believed to assist in the folding and solubilization of expressed
proteins. However, these large fusion partners may interfere
with the biological activity of the target proteins.
Considering that the expression of falcipain-1 in E. coli and
other expression systems has been problematic (9, 33), we
designed a number of constructs, all containing the mature
catalytic region of falcipain-1 along with different lengths of
the pro domain of the enzyme; pro domains are recognized to
play a major role in the folding and stability of many proteases
(37, 40, 41, 46). The construct F1.5 was a hybrid construct,
designed in a way that it expresses a 28-residue-long peptide
from the pro domain of the falcipain-2A sequence fused to the
mature region of falcipain-1. This peptide sequence has been
shown to play a crucial role in the folding process of falcipain-2
(37). Several attempts were made to express the five falcipain-1
constructs by using different E. coli expression vectors and a
variety of E. coli strains. Protein expression varied from poor to
reasonable levels. The pQE30 vector appeared to be more
suitable for constructs F1.4 and F1.5, while pET vectors gave
FIG. 4. Immunofluorescence images of fixed 3D7 P. falciparum parasites. (A) Merozoites costained with anti-F1.4 and anti-EBA-175 antibod-
ies. (B) Schizonts costained with anti-F1.4 and anti-EBA-175 antibodies. (C) Merozoites costained with anti-F1.4 and anti-MSP-119 antibodies.
FIG. 5. (A) Immunoblot analysis of P. yoelii lysate using anti-F1.4 antiserum (a) and when probed with preimmune sera (b). (B) Immunoflu-
orescence images of P. yoelii parasites immunostained with anti-F1.4 antibody.
VOL. 75, 2007 P. FALCIPARUM CYSTEINE PROTEASE WITH VACCINE POTENTIAL 2031
better results for F1.2 and F1.3. These results emphasize the
unpredictable nature of heterologous expression systems and
the need to try multiple expression systems/conditions (22).
All the recombinant falcipain-1 fragments were produced in
insoluble forms in different E. coli expression systems. To ob-
tain an active falcipain-1, proteins were solubilized in denatur-
ing conditions, purified by Ni2-NTA chromatography, and
refolded using different refolding conditions. The refolded fal-
cipain-1 proteins showed different levels of activity and yields.
The best activity and yield were obtained for F1.4 protein. The
F1.4 protein migrated as a monomer on gel permeation chro-
matography and showed a mobility shift on SDS-PAGE in
nonreducing conditions, thereby suggesting the formation of
disulfide bonds in the recombinant protein.
The results of fluorometric assays using the peptide sub-
strate Z-F-R-AMC showed that the protein is active at acidic
pH and the activity is significantly reduced at neutral pH. The
enzyme activity was completely abolished by cysteine protease
inhibitors, E-64 and leupeptin. These observations are in con-
tradiction with the findings of Goh et al. (9), who reported that
a recombinant falcipain-1 preparation was more active at neu-
tral pH than at acidic pH against the benzyloxycarbonyl-Leu-
Arg-7-amino-4-methyl-coumarin fluorogenic substrate. Fur-
ther, and more surprisingly, the most commonly used cysteine
protease inhibitor, E-64, did not inhibit the protease activity of
their preparation. Goh et al. expressed falcipain-1 as a fusion
partner with MBP, which showed no protease activity, leading
those workers to cleave off MBP with factor Xa protease to
obtain the recombinant falcipain-1 for biochemical character-
ization. It is not clear whether the observed discrepancies are
due to a difference in size or conformation of the recombinant
falcipain-1 preparations or to the method of production of the
protein. However, our results are in line with the earlier work
done with falcipain-1 by Salas et al. (33), although we failed to
observe any hemoglobin degradation by F1.4. A recent report
identified a 10-amino-acid motif in the C-terminal region of
falcipain-2 that binds hemoglobin (21). This motif is distant
from the enzyme active site and protrudes out from the pro-
tein. However, the sequence of the corresponding motif in
falcipain-1 varies considerably, and it remains to be seen
whether this motif in falcipain-1 binds to hemoglobin.
Parasite cysteine proteases have been shown to be immuno-
genic and are being exploited as serodiagnostic markers and
vaccine targets (15, 32). These cysteine proteases also seem to
play key roles in immunoevasion (1); enzyme activation, viru-
lence, and tissue and cellular invasion (18); excystment/encyst-
ment (47); and hatching and molting (16, 25). Anti-Fasciola
hepatica cathepsin L antibodies, anti-Dermatophagoides vivip-
arous cysteine protease, and anti-Dermatophagoides pteronys-
sinus Der p1 antibodies are inhibitory to the proteolytic activity
of these proteases (4, 43). Antibody-mediated protection has
been reported with P. falciparum SERA/SERP H antigens in
Aotus monkeys and mice (11, 45), with Leishmania major cys-
teine protease in mice (49), with Entamoeba histolytica cysteine
protease antigens in vitro (23), and also with Schistosoma man-
soni calpains (12). Possibilities for anti-cysteine protease vac-
cines against parasitic organisms has been reported for Fasci-
ola hepatica and Haemonchus contorius infections (6, 42, 43),
as well as for Trypanosoma cruzi (34, 35). Protection of mice
against gastric colonization by Helicobacter pylori by immuni-
zation with urease subunits A and B has also demonstrated
vaccine potential of proteases (5). These reports and recent
suggestions that falcipain-1 is involved in the merozoite inva-
sion of erythrocytes led us to explore the immunogenicity of
F1.4 in small animals.
Both mice and rabbits immunized with recombinant refolded
falcipain-1 (F1.4) elicited high humoral responses, indicating
the presence of both B- and T-cell epitopes in recombinant
F1.4. We used these anti-F1.4 antibodies for immunolocaliza-
tion and for invasion inhibition of erythrocytes by the malaria
parasite. The results show that falcipain-1 was localized in
discrete compartments in the schizont and merozoite stages,
and anti-falcipain-1 antibodies inhibited merozoite invasion by
30% (data not shown). We also studied the protective efficacy
of falcipain-1 in a mouse model against a heterologous P. yoelii
challenge. This model was chosen because the yoelipain-1 en-
zyme shows 55% sequence identity to falcipain-1 (28). A
characteristic infection was observed in naı¨ve mice, whereas
immunized mice showed a delay in the onset of infection and
a significant reduction in the total parasite burden. Impor-
tantly, immunized mice died much later than the control mice.
It seems that reduction in parasitemia observed in F1.4-immu-
nized mice is not sufficient to protect mice from death follow-
ing a challenge infection with a lethal strain of P. yoelii. Similar
results have been reported for mice immunized with malaria
vaccine candidate antigens and challenged with P. yoelii (30).
These results suggest that falcipain-1 may have a role in the
asexual blood stages of the malaria parasite. A recent study
using a falcipain-1-specific inhibitor (YA29) has also suggested
FIG. 6. (A) Parasitemia profiles of mice immunized with F1.4 and
falcipain-2 protein when challenged with P. yoelii sporozoites. The
percent parasitemia in mice was recorded for 35 days postchallenge.
(B) Percent survival of mice immunized with F1.4 and falcipain-2 when
challenged with P. yoelii sporozoites.
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a role for falcipain-1 in merozoite invasion (10). In contrast,
two more recent studies have shown that falcipain-1 knockout
parasites develop normally, indicating that falcipain-1 is not
essential for RBC invasion (7, 38). However, it is possible that
the loss of falcipain-1 function in the knockout parasite line is
compensated by other cysteine proteases or an alternate inva-
sion pathway that becomes operational when knockout para-
sites are selected under drug pressure, as seen in case of the
EBA-175 knockout parasite line (24). It is also possible that
while falcipain-1 might not be absolutely essential for P. fal-
ciparum, yoelipain-1 may yet have an essential role in the
intraerythrocytic cycle of P. yoelii, as indicated by the present
study. We were also able to use falcipain-2A immunization as
a separate control for our challenge experiment and found that
these immunized mice succumbed to infection much earlier
than the F1.4-immunized mice.
In conclusion, we show here that falcipain-1 can be ex-
pressed in an E. coli expression vector without any bulky fusion
partner. The refolded protein exists in monomeric form, is
enzymatically active, and can be used for structural studies.
The recombinant falcipain-1 is highly immunogenic and gen-
erates a protective immune response. These results suggest
that falcipain-1 may be further developed as a component of a
multistage, multisubunit vaccine.
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